Federica Medici

Dr. Federica Medici

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Emilia-Romagna, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FMFederica Medici
Federica Medici
MFMartina Ferioli
Martina Ferioli
LFLudovica Forlani
Ludovica Forlani
VLViola Laghi
Viola Laghi
JMJohnny Ma
Johnny Ma
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Locally advanced cervical cancer (LACC) is treated with concurrent chemoradiation (CRT). Predictive models could improve the outcome through treatment personalization. Several factors influence prognosis in LACC, but the role of systemic inflammation indices (IIs) is unclear. This study aims to assess the correlation between IIs and prognosis in a large patient cohort considering several clinical data. We retrospectively analyzed pretreatment IIs (NLR, PLR, MLR, SII, LLR, COP-NLR, APRI, ALRI, SIRI, and ANRI) in 173 LACC patients. Patient, tumor, and treatment characteristics were also considered. Univariate and multivariate Cox’s regressions were conducted to assess associations between IIs and clinical factors with local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Univariate analysis showed significant correlations between age, HB levels, tumor stage, FIGO stage, and CRT dose with survival outcomes. Specific pretreatment IIs (NLR, PLR, APRI, ANRI, and COP-NLR) demonstrated associations only with LC. The multivariate analysis confirmed Hb levels, CRT dose, and age as significant predictors of OS, while no II was correlated with any clinical outcome. The study findings contradict some prior research on IIs in LACC, emphasizing the need for comprehensive assessments of potential confounding variables.

25 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FMFederica Medici
Federica Medici
MFMartina Ferioli
Martina Ferioli
SCSilvia Cammelli
Silvia Cammelli
LFLudovica Forlani
Ludovica Forlani
VLViola Laghi
Viola Laghi
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Locally advanced cervical cancer represents a significant treatment challenge. Body composition parameters such as body mass index, sarcopenia, and sarcopenic obesity, defined by sarcopenia and BMI ≥ 30 kg/m2, have been identified as potential prognostic factors, yet their overall impact remains underexplored. This study assessed the relationship between these anthropometric parameters alongside clinical prognostic factors on the prognosis of 173 cervical cancer patients. Survival outcomes in terms of local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were analyzed using Kaplan regression methods—Meier and Cox. Older age, lower hemoglobin levels, higher FIGO (International Federation of Gynecology and Obstetrics) stages, and lower total radiation doses were significantly associated with worse outcomes. Univariate analysis showed a significant correlation between BMI and the outcomes examined, revealing that normal-weight patients show higher survival rates, which was not confirmed by the multivariate analysis. Sarcopenia was not correlated with any of the outcomes considered, while sarcopenic obesity was identified as an independent negative predictor of DFS (HR: 5.289, 95% CI: 1.298–21.546, p = 0.020) and OS (HR: 2.645, 95% CI: 1.275–5.488, p = 0.009). This study highlights the potential of sarcopenic obesity as an independent predictor of clinical outcomes. These results support their inclusion in prognostic assessments and treatment planning for patients with advanced cervical cancer.

10 October 2024 in Cancer Medicine
Verified
Journal Article
Open access
RRRomina Rossi
Romina Rossi
FMFederica Medici
Federica Medici
RHRagnhild Habberstad
Ragnhild Habberstad
PKPal Klepstad
Pal Klepstad
SCSavino Cilla
Savino Cilla
MMMarco Maltoni
Marco Maltoni
Background: The decision to administer palliative radiotherapy (RT) to patients with bone metastases (BMs), as well as the selection of treatment protocols (dose, fractionation), requires an accurate assessment of survival expectancy. In this study, we aimed to develop three predictive models (PMs) to estimate short‐, intermediate‐, and long‐term overall survival (OS) for patients in this clinical setting.Materials and Methods: This study constitutes a sub‐analysis of the PRAIS trial, a longitudinal observational study collecting data from patients referred to participating centers to receive palliative RT for cancer‐induced bone pain. Our analysis encompassed 567 patients from the PRAIS trial database. The primary objectives were to ascertain the correlation between clinical and laboratory parameters with the OS rates at three distinct time points (short: 3 weeks; intermediate: 24 weeks; prolonged: 52 weeks) and to construct PMs for prognosis. We employed machine learning techniques, comprising the following steps: (i) identification of reliable prognostic variables and training; (ii) validation and testing of the model using the selected variables. The selection of variables was accomplished using the LASSO method (Least Absolute Shrinkage and Selection Operator). The model performance was assessed using receiver operator characteristic curves (ROC) and the area under the curve (AUC).Results: Our analysis demonstrated a significant impact of clinical parameters (primary tumor site, presence of non‐bone metastases, steroids and opioid intake, food intake, and body mass index) and laboratory parameters (interleukin 8 [IL‐8], chloride levels, C‐reactive protein, white blood cell count, and lymphocyte count) on OS. Notably, different factors were associated with the different times for OS with only IL‐8 included both in the PMs for short‐ and long‐term OS. The AUC values for ROC curves for 3‐week, 24‐week, and 52‐week OS were 0.901, 0.767, and 0.806, respectively.Conclusions: We successfully developed three PMs for OS based on easily accessible clinical and laboratory parameters for patients referred to palliative RT for painful BMs. While our findings are promising, it is important to recognize that this was an exploratory trial. The implementation of these tools into clinical practice warrants further investigation and confirmation through subsequent studies with separate databases.

29 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
CDCostanza Maria Donati
Costanza Maria Donati
FMFederica Medici
Federica Medici
AZArina Alexandra Zamfir
Arina Alexandra Zamfir
EGErika Galietta
Erika Galietta
SCSilvia Cammelli
Silvia Cammelli
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Pediatric cancers, while rare, pose unique challenges due to the heightened sensitivity of developing tissues and the increased risk of long-term radiation-induced effects. Radiotherapy (RT) is a cornerstone in pediatric oncology, but its application is limited by concerns about toxicity, particularly secondary malignancies, growth abnormalities, and cognitive deficits. CyberKnife (CK), an advanced robotic radiosurgery system, has emerged as a promising alternative due to its precision, non-invasiveness, and ability to deliver hypofractionated, high-dose RT while sparing healthy tissues. This narrative review explores the existing evidence on CK application in pediatric patients, synthesizing data from case reports, small series, and larger cohort studies. All the studies analyzed reported cases of tumors located in the skull or in the head and neck region. Findings suggest CK’s potential for effective tumor control with favorable toxicity profiles, especially for complex or inoperable tumors. However, the evidence remains limited, with the majority of studies involving small sample sizes and short follow-up periods. Moreover, concerns about the “dose-bath” effect and limited long-term data on stochastic risks warrant cautious adoption. Compared to Linac-based RT and proton therapy, CK offers unique advantages in reducing session numbers and enhancing patient comfort, while its real-time tracking provides superior accuracy. Despite these advantages, CK is associated with significant limitations, including a higher potential for low-dose scatter (often referred to as the “dose-bath” effect), extended treatment times in some protocols, and high costs requiring specialized expertise for operation. Emerging modalities like π radiotherapy further underscore the need for comparative studies to identify the optimal technique for specific pediatric cases. Notably, proton therapy remains the benchmark for minimizing long-term toxicity, but its cost and availability limit its accessibility. This review emphasizes the need for balanced evaluations of CK and highlights the importance of planning prospective studies and long-term follow-ups to refine its role in pediatric oncology. A recent German initiative to establish a CK registry for pediatric CNS lesions holds significant promise for advancing evidence-based applications and optimizing treatment strategies in this vulnerable population.

22 August 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
FMFederica Medici
Federica Medici
DADaniel Aeberold
Daniel Aeberold
JCJozefina Casuscelli
Jozefina Casuscelli
LELouise Emmett
Louise Emmett
Stefano FantiStefano Fanti
Stefano Fanti
Savino CillaSavino Cilla
Savino Cilla
Salvage radiotherapy (SRT) is the standard treatment for biochemical recurrence (bREC) after radical prostatectomy (RP), yet optimal radiation dose, field size, and the role of advanced imaging like PSMA-PET remain unclear. This study assessed the impact of SRT dose and the prognostic role of PSMA-PET on 2-year biochemical relapse-free survival (bRFS) in patients with localized disease. In this retrospective multicenter study, 255 patients treated with SRT across 11 centers were selected from a database of 1,201 cases. Inclusion criteria included PSA persistence/recurrence (≥0.1 ng/mL) post-RP and negative PSMA-PET for nodal or distant metastases. Patients receiving androgen deprivation therapy or with PSA > 0.5 ng/mL pre-SRT were excluded. Prognostic factors were identified using LASSO analysis and modeled with CART analysis. The primary endpoint was 2-year bRFS. With a median follow-up of 33 months, 2-year bRFS was 88.2 %. Lower pre-SRT PSA (<0.2 ng/mL), PSMA-PET negativity, longer PSA doubling time, older age, favorable ISUP grades (1-2), and shorter intervals from surgery to bREC were associated with improved bRFS. CART analysis demonstrated that PSMA-PET findings significantly influenced prognosis in patients with PSA levels below 0.2 ng/mL, while PSA-doubling time was predictive in patients with PSA 0.2-0.5 ng/mL. SRT dose and elective nodal irradiation did not significantly affect bRFS. This study underscores the complexity of prognostic modeling in SRT for prostate cancer, highlighting the value of PSMA-PET and CART for refined risk stratification.

6 November 2023 in Radiology Case Reports
Verified
Journal Article
Open access
FMFederica Medici
Federica Medici
SSSilvia Strolin
Silvia Strolin
PCPaolo Castellucci
Paolo Castellucci
SCSavino Cilla
Savino Cilla
VLViola Laghi
Viola Laghi
SCSilvia Cammelli
Silvia Cammelli
In the management of symptomatic inoperable retroperitoneal sarcomas (RPS), palliative radiotherapy (RT) is a potential treatment option. However, the efficacy of low doses used in palliative RT is limited in these radioresistant tumors. Therefore, exploring dose escalation strategies targeting specific regions of the tumor may enhance the therapeutic effect of RT in relieving or preventing symptoms.